Tait, Paul

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Pinato, D. J., Cortellini, A., Sukumaran, A., Cole, T., Pai, M., Habib, N., Spalding, D., Sodergren, M. H., Martinez, M., Dhillon, T., et al. (2021) · BMC Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 79

Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma

D'Alessio, A., Pai, M., Spalding, D., Goldin, R. D., Scheiner, B., Korolewicz, J., Fulgenzi, C. A. M., Ward, C., Yip, V., Slater, S., et al. (2023) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 17